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Clinics and pathology 
Disease 
Chronic myelogenous leukaemia (CML) 
Epidemiology 
+8 is one of the major anomalies additional to the 
t(9;22), with i(17q), + der(22), before +19; found as 
a unique additional anomaly in 10%, with other in 
25% of CML cases with clonal evolution; these 
additional anomalies may be present at the 
diagnosis of CML (in 10%, possibly with 
unfavourable significance), or may appear during 
course of the disease, they do not indicate the 
imminence of a blast crisis, although they also 
frequently emerge at the time of acute 
transformation; +8 is more often found in the 
myeloid than in the lymphoid blast crisis. 
Prognosis 
+8 has apparently no prognostic significance in 
CML. 
Disease 
Other chronic myeloproliferative diseases: 
polycytemia vera (PV), and idiopathic 
myelofibrosis (but not found in essential 
thrombocythemia). 
Epidemiology 
+8 is found in 20% of PV cases with an abnormal 
karyotype, mostly as the sole anomaly, may be 
accompanied with +9 (abnormal karyotypes in PV 
occur mainly with evolution, but the appearance of 
a clonal anomaly does not indicate progression of 
the disease); +8 is found in 10% of myelofibrosis 
cases with chromosome anomalies, sometimes with 
+9. 
Prognosis 
No prognostic significance. 
Disease 
Myelodysplastic syndromes (MDS): refractory 
anaemia (RA), refractory anaemia with ring 
sideroblasts (RARS), refractory anaemia with 
excess of blasts ± in transformation (RAEB±T), 
chronic myelomonocytic leukaemia (CMML). 
Note 
The present (unpublished) review of about 250 
ANLL cases with +8 is a review of literature cases 
and may therefore be biased, although the 
percentages herein given are in accordance with 
those of large series. 
Epidemiology 
+8 is found in 15-20% of MDS; 5-10% of MDS 
with +8 are treatment-related MDS; +8 is present in 
each FAB subgroup: up to 30% of RARS cases 
have +8; 15-20% of other subgroups have +8. 
+8 is: the sole anomaly in 55%, found with simple 
karyopypic changes in 20%, and part of a complex 
karyotype in the remaining 25% of cases. 
Altogether, sex ratio is 1.5M/1F (1.8/1 in cases 
RAEB±T and CMML, 1/1 in RA or RARS). 
- 15% of +8/MDS are found with -5/del(5q), often 
in complex karyotypes. 
- 4% of +8/MDS are found with 
t(1;7)(q10;p10)(and 20% of t(1;7)/MDS-ANLL also 
associate +8). 
- 4% as well are found with del(20q), mainly in 
simple karyotypes. 
- +8 is strickingly found in independant subclones, 
with other subclones carrying other anomalies, in 
particular del(5q) or t(1;7) (e.g.: 46, XY, 
del(5q)/47, XY, +8). 










Median survival would near 2 years. 
Disease 
Acute non lymphocytic leukaemias (ANLL) 
Note 
The present (unpublished) review of more than 500 
ANLL cases with +8 is a review of literature cases 
and may therefore be biased, although the 
percentages herein given are in accordance with 
those of large series; we also add 39 unpublished 
t(11;19) to 101 published cases. 
Epidemiology 
+8 is found in 10-15% of ANLL; 10% of ANLL 
with +8 are treatment-related ANLL; +8 is present 
in each FAB subgroup (from M1 to M7) in a 
grossly equivalent percentage (but in M5a where 
the percentage is higher), in contrast to what has 
been previously claimed; cases may present with a 
preceeding myelodysplasia. 
+8 is: the sole anomaly in 40%, found with simple 
karyopypic changes in 35%, and part of a complex 
karyotype in the remaining 25% of cases. 
altogether, sex ratio is 1.2/1 (1.6/1 in cases with a 
complex karyotype, 1/1 otherwise). 
- 5-10% of +8/ANLL are found with -
5/del(5q)and/or -7/del(7q), often associated, and 
nearly always in complex karyotypes. 
- 5-10% also are found in t(15;17)/M3 cases, 
mostly as a single additional anomaly, while 1/3 of 
t(15;17) are accompanied with +8. 
- 5-10% are found with inv(16), mainly in simple 
karyotypes (and 15% of inv(16) cases also carry 
+8). 
- 5% are associated with +21, often parts of a 
complex karyotype. 
- 5% also are found in 11q23 ANLL, mostly in 
t(9;11)(p22;q23) cases (and 20% of t(9;11) also 
carry +8, while 15% of t(11;19)(q23;p13.3)/ANLL 
or ALL (91 cases, 25 unpublished), 10% of 
t(6;11)(q27;q23)/ANLL, t(10;11)(p12;q23)/ANLL, 
and t(11;19)(q23;p13.1)/ANLL (49 cases, 14 
unpublished) as well, and only 3% of 
t(4;11)(q21;q23)/ALL, have an additional 8 
chromosome. 
- Less than 5% are found with t(8;21)(q21;q21) 
often in simple karyotypes, and 10% of t(8;21) 
associate +8. 
- Less than 5% also are associated with 
t(9;22)(q34;q11)/ANLL, mostly in complex 
karyotypes. 
- 2% are associated with +9, either in simple or in 
complex karyotypes. 
- 1% of +8/ANLL are found with t(1;7)(q10;p10), 
but as far as 20% of t(1;7) also associate +8. 
- 15% of Down syndrome patients with 
MDS/ANLL have +8 in their leukaemic cells. 
Clinics 
From 2 studies on ANLL in adults with +8 solely: 
no specific FAB subgroup; median age was 60 
years (vs 50 years in cases of +8 accompanying 
t(8;21), t(15;17) or inv(16)); no gross 
organomegaly; moderate WBC. 
Prognosis 
Of ANLL in adults with +8 solely: complete 
remission in 60-70% (vs 90% in cases 
accompanying t(8;21), t(15;17) or inv(16)); median 
survival was 13 months in one study, 20 months in 
another; taking all +8 cases, solely or not, median 
survival would be of about a year; +8 does not seem 
to alter the relatively good prognosis of t(8;21), 
t(15;17) or inv(16), while the (numerous) cases 
with a complex karyotype exhibit a poor outcome; 
age is an adverse feature. 
Disease 
Acute lymphocytic leukaemia (ALL) 
Phenotype/cell stem origin 
+8 is more often found in B-cell than in T-cell 
cases. 
Epidemiology 
- +8 is a rare anomaly in lymphoid malignancies 
(90% of +8 occur in myeloid malignancies); found 
in about 5% of ALL. 
- Rarely found as a sole anomaly (5-10%), may be 
part of hyperploid karyotypes (>50 chromosomes 
mainly) without structural anomalies (20% of 
cases), mostly found in complex karyotypes with 
structural anomalies (2/3 of cases), these complex 
karyotypes being often hyperploid as well. 
- Sex ratio: 1.5/1. 
- Accompany (mostly in complex karyotypes): 
t(9;22)(q34;q11)/ALL, t(4;11) (see above) and 
other 11q23, del(6q), t(1;19)(q23;p13), dic(9;12) 




+8 is exceptional; has been found associated with 
t(14;18)(q32; q21), t(8;14)(q24;q32), and other 
known or unknown anomalies. 
Disease 
Chronic lymphoproliferative diseases 
Epidemiology 
Very rare anomaly (to be noted that +8 is  
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exceptional in T-prolymphocytic leukaemia, in 
contrast with the freqency of i(8q), which occurs by 
completely different mechanisms, but gives, for 
parts, very similar genetic imbalances). 
Genetics 
Note 
Genes (possibly) involved are unknown. 
To be noted 
Note 
Karyotypes with +8 may be misinterpreted with a 
possible overlooked constitutional trisomy 8, a 
syndrome associating mild to moderate mental 
delay and (sometimes mild as well) bone 
anomalies; furthermore constitutional trisomy 8 has
been said to be at increased rirk of cancers, 
haematological malignancies in particular. 
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